J

Johnson & Johnson

Makes prescription drugs and medical devices

Manager, Full Stack Engineer - Software Engineering

Full-TimeUpdated on 10/24/2026
No salary listed
Expert
Bachelor's, Master's
Hyderabad, Telangana, India
HybridHybrid work in Hyderabad, India.
Engineering ManagementEngineering Leadership

About the job

Requirements
  • A Bachelor's degree in Computer Science, Engineering, Information Technology, Software Engineering, or a related field is required.
  • A Master's degree is preferred.
  • At least 10 years of experience in software engineering, full stack development, enterprise application delivery, or digital product engineering is required.
  • At least 5 years of people leadership experience managing engineering teams, technical leads, or distributed delivery teams is required.
  • Proven experience delivering enterprise-scale applications using modern front-end, back-end, API, and cloud technologies is required.
  • Experience implementing Agile, DevSecOps, continuous integration/continuous delivery, automated testing, and production support practices is required.
  • Experience working with global stakeholders and cross-functional technology teams in a matrixed organization is required.
  • Knowledge of React, Angular, or modern JavaScript frameworks; TypeScript or JavaScript; HTML5; CSS3; responsive design; accessibility; and UX collaboration is required.
  • Knowledge of Java, .NET, Node.js, or Python; REST APIs; microservices; API security and authentication; relational and NoSQL databases; and event-driven integrations is required.
  • Knowledge of Azure or AWS; containers; Kubernetes; continuous integration/continuous delivery pipelines; infrastructure as code; monitoring; logging; observability; secure software development lifecycle; automated testing; code quality and reviews; Agile delivery; architecture and design patterns; and production support is required.
Responsibilities
  • Lead, mentor, and develop a high-performing team of full stack engineers, technical leads, and application developers.
  • Set engineering standards for secure coding, architecture, code quality, testing, observability, and production readiness.
  • Drive technical excellence through design reviews, code reviews, reusable patterns, and engineering communities of practice.
  • Build a culture of ownership, innovation, inclusion, continuous improvement, and accountability.
  • Lead development of modern web applications, APIs, services, dashboards, portals, workflow applications, and digital products.
  • Guide architecture and implementation across front-end, back-end, integration, database, authentication, and deployment layers.
  • Ensure solutions are scalable, maintainable, secure, accessible, performant, and aligned with enterprise technology standards.
  • Partner with Product Management and UX teams to translate user needs into intuitive, reliable, and valuable digital experiences.
  • Drive adoption of cloud-native design patterns, microservices, API-first architecture, containerization, and managed cloud services.
  • Collaborate with enterprise architecture and platform engineering teams to define reusable application patterns and reference architectures.
  • Ensure effective use of cloud capabilities for resiliency, monitoring, cost optimization, automation, and scalability.
  • Support modernization of legacy applications into modern, modular, and cloud-ready technology platforms.
  • Implement continuous integration/continuous delivery pipelines, automated testing, quality gates, security scans, infrastructure automation, and release management practices.
  • Establish operational key performance indicators covering reliability, performance, deployment frequency, incident trends, and service health.
  • Partner with cybersecurity, privacy, and quality teams to ensure secure software development lifecycle practices.
  • Drive root cause analysis, technical debt reduction, application rationalization, and continuous platform improvement.
  • Lead Agile delivery teams using Product Operating Model principles and outcome-focused execution.
  • Collaborate with business stakeholders, product owners, architects, data teams, AI teams, testing teams, and vendor partners.
  • Create delivery roadmaps, manage dependencies, mitigate risks, and communicate progress to senior stakeholders.
  • Balance speed, quality, compliance, user needs, and long-term sustainability in technology decisions.
  • Ensure applications comply with applicable enterprise security, privacy, quality, accessibility, and regulatory requirements.
  • Support delivery practices aligned with GxP, Computer System Validation, GDPR, HIPAA, and internal technology standards where applicable.
  • Maintain audit-ready engineering documentation, traceability, and release evidence for regulated applications.
  • Promote responsible use of data and AI-enabled capabilities within application experiences.
Desired Qualifications
  • Experience in Pharmaceutical, Healthcare, Life Sciences, or other regulated industries.
  • Experience leading teams that build applications for Clinical Development, R&D, Medical Affairs, Regulatory, or enterprise data platforms.
  • Experience integrating digital applications with data platforms, analytics, AI services, workflow tools, and enterprise identity platforms.
  • Experience with Product Operating Model, platform thinking, reusable engineering assets, and product-based delivery.
  • Relevant certifications in Azure, AWS, software architecture, Agile, DevOps, cybersecurity, or application engineering.
  • Strong executive interpersonal skills and the ability to simplify sophisticated technology topics for business stakeholders.

About the company

Johnson & Johnson develops prescription medicines and makes medical devices for hospitals, and unlike most big drugmakers, it runs both businesses under one roof. In 2015, its Darzalex became the first antibody drug approved for multiple myeloma, a blood cancer. Its medicines treat cancer, immune diseases such as psoriasis, and mental illnesses such as depression, and patented drugs bring in most of its sales. Its MedTech unit makes heart pumps, catheters that treat irregular heartbeats, surgical sutures, and Acuvue contact lenses. It was founded in 1886 to make sterile surgical dressings, is based in New Brunswick, New Jersey, and spun off its consumer brands, such as Tylenol and Band-Aid, as Kenvue in 2023.

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, New Jersey

Founded

1886

Get referred to Johnson & Johnson

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Cancer drugs drive growth: oncology sales rose 17% to $7.4 billion in the June 2026 quarter, 29% of the total.
  • Stock grants have gained value: J&J shares rose 58% in the year to September 2026, versus 23% for Pfizer.
  • Students have a way in: J&J listed 1,897 open jobs in October 2026, including 201 internships, co-ops and early-career roles.

What critics are saying

  • Its key immune drug trails: AbbVie's Skyrizi outsold Tremfya $5.5 billion to $2.0 billion in the June 2026 quarter.
  • Orthopedics is leaving J&J: in September 2026, it was negotiating a $20 billion sale to buyout firm Apollo.
  • Baby powder suits remain costly: in July 2026, J&J agreed to pay $5.5 billion to end about 76,000 cancer claims.

What makes Johnson & Johnson unique

  • Its debt is rated safer than America's: S&P's top AAA rating goes to only two US companies, J&J and Microsoft.
  • Employees rank above shareholders: J&J's 1943 Credo lists duties to patients, then staff and communities, with stockholders last.
  • Its psoriasis pill is a first: Icotyde, approved March 2026, blocks an immune signal rivals target only by injection.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays
  • Remote Work Options
  • Performance Bonus

Growth & Insights and Company News

6 month growth

6%

1 year growth

-2%

2 year growth

-2%
Yahoo Finance
Oct 23rd, 2026
Smith & Nephew's $22B talks to buy J&J's orthopaedics unit collapse over who would lead

Smith & Nephew's merger talks with Johnson & Johnson (J&J) over its orthopaedics unit collapsed over who would lead the combined company, the Financial Times reported. The sides had reportedly agreed on the main financial terms and the deal structure. J&J wanted Namal Nawana, who runs its orthopaedics unit and formerly led Smith & Nephew, to lead the business. Smith & Nephew wanted current chief executive officer Deepak Nath to stay. Smith & Nephew's offer valued J&J's hip and knee unit at up to $22 billion, almost double its own market value. J&J shareholders would have owned 50.1% of the combined company. J&J is leaning toward spinning off the unit as DePuy Synthes, targeting mid-2027. Reuters reported the unit sought around $20 billion and drew private equity interest. Both companies declined to comment.

Yahoo Finance
Oct 23rd, 2026
ETFs sell $54.1M of Johnson & Johnson, extending two-day selling streak

ETFs sold a net $54.1 million of Johnson & Johnson (JNJ) shares on Wednesday, extending a two-day run of net selling. Twenty-five funds cut their holdings, 24 added shares, and 153 held steady. The Health Care Select Sector SPDR (XLV) led the selling, cutting 153,134 shares worth $39.5 million. The iShares Core S&P 500 ETF (IVV) sold $11.5 million, and the iShares MSCI USA Momentum Factor ETF (MTUM) sold $5.4 million. Tuesday saw net selling of $20.0 million, after net buying of $38.1 million on Monday and $84.4 million on October 16. JNJ has a market cap of $644.9 billion and has returned 31.39% year to date.

Yahoo Finance
Oct 22nd, 2026
JNJ rated buy with $289 target as pharma growth of 8% outpaces MedTech's 2.5%

Johnson & Johnson (JNJ) earns a "buy" rating from 24/7 Wall St., with a 12-month price target of $288.66. That implies 11.48% upside from the $258.93 close on October 20. Growth is coming from pharma. Innovative Medicine sales rose 7.9% last quarter, while MedTech grew 2.5%. The analyst says the stock hinges on whether devices can close that gap. Third-quarter sales reached $25.4 billion. Adjusted earnings per share (EPS) were $2.59, but GAAP EPS fell to $0.09 after about $7 billion of charges, mostly tied to a proposed talc settlement and two deals. Management cut adjusted EPS guidance to $11.05 to $11.15. The bull case is $302.93, or 17% upside. Tremfya grew 68%, and management expects it to become a $10 billion-plus franchise.

Yahoo Finance
Oct 20th, 2026
Johnson & Johnson and Amgen beat the market in 2026, but can the dividend stocks keep going?

Johnson & Johnson and Amgen, two dividend stocks that have beaten the broader market this year, could suit investors bracing for a possible crash. J&J's latest quarter beat expectations, and it slightly raised its 2026 guidance. But its medtech unit is struggling, as demand for the Impella heart pump has fallen amid safety questions and a US Class 1 recall. Long-term, it has new drugs, a robotic surgery system approved in the US, and a proposed $5.5 billion talc settlement. It is a Dividend King with 64 straight years of payout increases. Amgen's second-quarter revenue rose 10% to $10.1 billion, despite pressure on Tavneos and falling denosumab sales. It has raised payouts 152% over a decade and offers a 2.3% forward yield, against 1.1% for the S&P 500.

Yahoo Finance
Oct 17th, 2026
Johnson & Johnson dips after $25.4B quarter: buy the Dividend King?

Johnson & Johnson shares fell after the healthcare group reported third-quarter results, despite a beat-and-raise quarter. Revenue rose 5.9% to $25.4 billion, while adjusted earnings per share fell 7.5% to $2.59, a drop attributed mostly to acquisitions. Innovative medicine sales rose 7.7% to $16.8 billion, led by cancer drug Darzalex ($4.2 billion) and Tremfya ($2.4 billion, up 68.3%). The company raised its 2026 operational sales guidance to $100.7 billion at the midpoint, from $100.6 billion. Medtech revenue grew just 2.5% to $8.6 billion, which drove the share dip. Safety and efficacy concerns over its Impella heart pumps hurt the cardiovascular unit abroad. The company has raised its dividend for 64 consecutive years, making it a Dividend King.